EARN25

2 Healthcare Stocks To Avoid This Month

The pullbacks from VRTX and BSX could continue this month

Managing Editor
Nov 1, 2018 at 12:44 PM
facebook X logo linkedin


Biotech name Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) and medical device stock Boston Scientific Corporation (NYSE:BSX) both had subpar Octobers, pulling back amid the broader market sell-off. And while both stocks are trading higher today, the selling could be far from exhausted, if history is any guide.

VRTX's Rough Quarter Could Get Worse

According to Schaeffer's Senior Quantitative Analyst Rocky White, Vertex Pharmaceuticals stock has been one of the worst stocks to own on the S&P 500 Index (SPX) in November, looking at data from the past 10 years. Specifically, VRTX has averaged a monthly loss of 3.65%, with just four of those returns positive.

On the charts, the biotech stock is fresh off its worst month since October 2016, pressured by a competitor's cystic fibrosis drug breakthrough. The equity gapped lower in late October after earnings, and has racked up a fourth-quarter deficit of nearly 12% so far. 

Daily Stock Chart VRTX

Despite the struggles, analysts are all in on VRTX. Of the 20 brokerages covering the security, 18 rate it a "buy" or better, with zero "sells" on the books. In addition, its consensus 12-month price target of $196.32 is a 14% premium to its current perch of $171.86.

In the options pits, puts have been bought to open over calls at an accelerated clip. VRTX's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands at 2.53 and ranks in the 98th annual percentile. 

Analysts, Options Traders Bullish on BSX

Boston Scientific stock was up 1.2% to trade at $36.55, at last check. Since topping out at a 14-year high of $39.44 on Oct. 2, the stock has shed 7.3%. Plus, over the last 10 years, BSX has averaged a November loss of 3.78%, with just four of those returns positive.

Worst Stock November BSX

Like Vertex, analysts are quite bullish on Boston Scientific, with 21 of the 23 brokerages rating it a "strong buy." BSX options traders are upbeat, too. This is based on the security's 50-day put/call volume ratio of 5.895 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), high enough to rank in the 88th annual percentile.

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!